- No mas: Principal bans Spanish language in intercom announcement
- Hacking software could put ‘zombie drone army’ in user’s hands
- Support for stricter gun laws drops: poll
- 10 whales dead, 41 others stranded in Everglades
- John Boehner faces bipartisan pressure to allow gay-rights vote
- Martin Bashir resigns from MSNBC over ‘ill-judged’ comments about Sarah Palin
- Rep. Duncan Hunter: While Obama prays for Iranian change, U.S. should ready its nukes
- Best company ever? Veteran Beer Co. exists to employ vets, provide quality beer
- Iran official: Sanctions ‘utterly failed’ to stop nuclear program
- ‘Black Santa’ display at IU sparks student outrage
Summary Box: Medicare panel backs Provenge
VOTE OF CONFIDENCE: Medicare advisers said they are confident in the benefits of Provenge, an innovative prostate cancer drug that has generated controversy because of its $93,000 price tag. Medicare will make a final decision on whether to pay for the drug in March.
HURDLE CLEARED: The positive vote is a win for the drugmaker Dendreon Corp., because most prostate cancer patients get their health coverage through Medicare, the federal program that covers 47 million elderly and disabled patients.
PUSHBACK: Some patients and politicians have protested Medicare’s review of the drug. They say the government should automatically pay for the drug because it already has been declared safe and effective by the Food and Drug Administration.
By Tom Harris and Madhav Khandekar
Bad science puts rich nations on the hook for trillions in climate liabilities
- Angry NTSB ousts railroad union from N.Y. train crash site
- Hola: Boehner prepares to push amnesty bill through House
- Kill team: Obama war chiefs widen drone death zones
- Puerto Rico caravan honoring Paul Walker ends in 6 drunken-driving arrests, 72 speeding tickets
- Apple wins facial recognition patent for iPhone 6
- Xbox One, Playstation 4 games penalize users for cursing in their own homes
- First Dog Sunny knocks down Ashtyn Gardner; Michelle Obama yanks leash
- Inside China: Nuclear submarines capable of widespread attack on U.S.
- HURT: Postal Service misses address by a whole continent
- Allen West warns Obamas backdoor gun control is moving forward
Independent voices from the The Washington Times Communities
Criticism may not be agreeable, but it is necessary. It fulfills the same function as pain in the human body. It calls attention to an unhealthy state of things.
Wall Street news for retail investors who want to know what's going on.
Does it take over 25 years in public service to really know what goes on in Washington?
Despite cynicism about the law, it can provide you justice, protection, and ensure your rights.